Speedy Approval Of Roche's Zelboraf Puts Pressure On Bristol's Yervoy
This article was originally published in The Pink Sheet Daily
Executive Summary
Personalized melanoma medicine vemurafenib set to sell for $9,400 a month, says Genentech. Genetic testing should be available right away.